CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Grant or award Director acquired 48,838 shares (grant or award)
- 4 Grant or award Atillasoy Ercem acquired 23,256 shares (grant or award)
- 4 Grant or award General Counsel acquired 23,256 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 315,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 23,256 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 65,725 shares at an average $7.48 ($491,850)
- 4 Open-market sale Chief Commercial Officer sold 516 shares at $9.01 ($4,651)
- 4 Open-market sale Chief Commercial Officer sold 15,322 shares at $8.32 ($127,525)
- 4 Open-market buy Director bought 5,000 shares at $8.87 ($44,350)
- 4 Open-market sale Atillasoy Ercem sold 4,639 shares at $8.24 ($38,248)
- 4 Open-market sale Director sold 17,100 shares at $8.01 ($136,889)
- 4 Open-market sale Chief Commercial Officer sold 4,656 shares at $8.75 ($40,752)
- 4 Open-market sale Chief Accounting Officer sold 1,563 shares at $8.75 ($13,680)
- 4 Open-market sale Director sold 6,450 shares at $8.75 ($56,454)
- 4 Open-market sale Chief Commercial Officer sold 514 shares at $17.06 ($8,770)
- 4 Open-market sale Chief Commercial Officer sold 15,203 shares at $21.13 ($321,262)
- 4 Open-market sale Chief Scientific Officer sold 20,988 shares at an average $22.18 ($465,559)
- 4 Open-market sale Director sold 800 shares at $24.77 ($19,812)
Page 13 of 19 · 363 filings